The New round of Quantitative Easing

As jobs start to get back into the economy, stability is still a long way away and the Ed is unlikely to start raising rates too soon, instead use the money from sold investments/junk to buy more liquidity for the Us and thence the world is to get more easy money flows to keep propping growth till the inflation pop gets someone too squeamish

in reference to:

"S. | Asia | Europe | Wires Did the Fed Just Tip Its Hand To a Third Round of Easing? With a subtle wave of his baton, the second coming of the Maestro may have started the music for another round of Federal Reserve monetary easing. Fed Members Agree to Keep Stimulus Plan, Low Rates"
- Did Fed Just Tip Hand to Third Round of Easing? - CNBC (view on Google Sidewiki)

YES BANK results are in

as usual trading room is buzzing and index has moved up anotch

in reference to: Editing a post - Posterous (view on Google Sidewiki)

J&J and Novartis get help from a large cash outgo as they report good , better and better results

Novartis spent $51 billion in Alcon to add $1.9 billion sales in the current 2011 quarter, J&J managed to improve earnings to close to $3.77 billion excluding litigation costs to $1.35 per share while counterbalancing its medical device revenues of $2 billion with a pitch for Synthes. Core Earnings at Novartis were up to $1.41 per share despite sales lowerby $1.1 billion in anti-flu sales and more expected in reducing Diovan

Constant currency sales at Novartis topped $14 billion and J&J sales topped $16.1 billion. International sales were mostly responsible for the J&J recovery at 7% up tickImage via Wikipedia

Write text here...

Related articles

• After Pfizer and Merck, J&J gets up to go | Advantage Research (advantages.us)
• You: Novartis net profits fall 4% on Alcon costs (france24.com)